Delayed Pseudoprogression in Glioblastoma Patients Treated With Tumor-Treating Fields

被引:0
|
作者
Saito, Norihiko [1 ]
Hirai, Nozomi [1 ]
Sato, Sho [1 ]
Hayashi, Morito [1 ]
Iwabuchi, Satoshi [1 ]
机构
[1] Toho Univ, Neurosurg, Ohashi Med Ctr, Tokyo, Japan
关键词
electric fields; glioblastoma multiforme; temozolomide; radiation therapy; pseudoprogression; ttfields; glioblastoma; TEMOZOLOMIDE; RADIOTHERAPY; BEVACIZUMAB; TRIAL;
D O I
10.7759/cureus.55147
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumor-treating fields (TTFields) is an established treatment modality for glioblastoma. False progression to chemoradiation is a known problem in patients with glioblastoma multiforme (GBM), with most cases occurring within three months of radiation therapy. In this report, we present two cases of delayed pseudoprogression caused by TTFields. Two patients with GBM who received TTFields showed signs of radiographic progression six months after the completion of radiation therapy. Patient 1 was a 37-year-old female with a glioblastoma in the right temporal lobe. Patient 2 was a 70-year-old male with glioblastoma in the left temporal lobe. Both patients received radiation therapy, followed by temozolomide (TMZ) maintenance therapy and TTFields. Patient 1 underwent a second resection; however, the pathology revealed only a treatment effect, and the final diagnosis was a pseudoprogression. In Case 2, the disease resolved with steroid therapy alone. In both patients, the lesions appeared later than during the typical pseudoprogression period. A recent study reported that TTFields increase the permeability of the plasma cell membrane, which may result in further leakage of gadolinium into the extracellular lumen. Further studies are needed to better characterize delayed pseudoprogression and improve treatment outcomes.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields
    Kwan, Kevin
    Schneider, Julia R.
    Boockvar, John A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (17): : 1822 - 1823
  • [2] Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields Reply
    Stupp, Roger
    Ram, Zvi
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (17): : 1823 - 1823
  • [3] A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS
    Peters, Katherine
    Affronti, Mary
    Kim, Jung-Young
    Patel, Mallika
    Johnson, Margaret
    Bartlett, David
    Cort, Nicole
    Lipp, Eric
    Iden, Deborah
    Broadwater, Gloria
    Herndon, James
    Landi, Daniel
    Khasraw, Mustafa
    Desjardins, Annick
    Friedman, Henry
    Ashley, David M.
    NEURO-ONCOLOGY, 2021, 23 : 184 - 185
  • [4] Rationale and Background on Tumor-Treating Fields for Glioblastoma
    Schwartz, Margaret A.
    Onuselogu, Lynnette
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2016, 20 (05) : 20 - 24
  • [5] Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy
    Saria, Marlon Garzo
    Kesari, Santosh
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2016, 20 (05) : 9 - 13
  • [6] Early metabolic response to tumor-treating fields in patients with recurrent glioblastoma
    Mittal, Sandeep
    Barger, Geoffrey R.
    Bosnyak, Edit
    Shah, Varun B.
    Juhasz, Csaba
    CANCER RESEARCH, 2017, 77
  • [7] Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields
    Aaron Michael Rulseh
    Jiří Keller
    Jan Klener
    Jan Šroubek
    Vladimír Dbalý
    Martin Syrůček
    František Tovaryš
    Josef Vymazal
    World Journal of Surgical Oncology, 10
  • [8] Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields
    Rulseh, Aaron Michael
    Keller, Jiri
    Klener, Jan
    Sroubek, Jan
    Dbaly, Vladimir
    Syrucek, Martin
    Tovarys, Frantisek
    Vymazal, Josef
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
  • [9] THE COST-EFFECTIVENESS OF TUMOR-TREATING FIELDS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Armoiry, X.
    Auguste, P.
    Dussart, C.
    Guyotat, J.
    Connock, M.
    NEURO-ONCOLOGY, 2019, 21 : 68 - 68
  • [10] TUMOR-TREATING FIELDS THERAPY IS COMPATIBLE WITH STANDARD CHEMORADIOTHERAPY FOR GLIOBLASTOMA
    Stachelek, Gregory
    Grimm, Jimm
    Lim, Michael
    Bettegowda, Chetan
    Redmond, Kristin
    Kleinberg, Lawrence
    NEURO-ONCOLOGY, 2018, 20 : 228 - 228